291 related articles for article (PubMed ID: 19611406)
1. Tissue-specific, non-invasive toxicity biomarkers: translation from preclinical safety assessment to clinical safety monitoring.
Muller PY; Dieterle F
Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1023-38. PubMed ID: 19611406
[TBL] [Abstract][Full Text] [Related]
2. Preclinical predictors of clinical safety: opportunities for improvement.
Sistare FD; DeGeorge JJ
Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
[TBL] [Abstract][Full Text] [Related]
3. Serum chemical biomarkers of cardiac injury for nonclinical safety testing.
Walker DB
Toxicol Pathol; 2006; 34(1):94-104. PubMed ID: 16507550
[TBL] [Abstract][Full Text] [Related]
4. Future of toxicology--mechanisms of toxicity and drug safety: where do we go from here?
Stevens JL
Chem Res Toxicol; 2006 Nov; 19(11):1393-401. PubMed ID: 17112225
[TBL] [Abstract][Full Text] [Related]
5. The discovery and development of proteomic safety biomarkers for the detection of drug-induced liver toxicity.
Amacher DE
Toxicol Appl Pharmacol; 2010 May; 245(1):134-42. PubMed ID: 20219512
[TBL] [Abstract][Full Text] [Related]
6. Safety biomarkers and the clinical development of oncology therapeutics: considerations for cardiovascular safety and risk management.
Fingert H; Varterasian M
AAPS J; 2006 Mar; 8(1):E89-94. PubMed ID: 16584137
[TBL] [Abstract][Full Text] [Related]
7. Current challenges in the evaluation of cardiac safety during drug development: translational medicine meets the Critical Path Initiative.
Piccini JP; Whellan DJ; Berridge BR; Finkle JK; Pettit SD; Stockbridge N; Valentin JP; Vargas HM; Krucoff MW;
Am Heart J; 2009 Sep; 158(3):317-26. PubMed ID: 19699852
[TBL] [Abstract][Full Text] [Related]
8. Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies.
Muller PY; Brennan FR
Clin Pharmacol Ther; 2009 Mar; 85(3):247-58. PubMed ID: 19177065
[TBL] [Abstract][Full Text] [Related]
9. Qualified kidney biomarkers and their potential significance in drug safety evaluation and prediction.
Xie HG; Wang SK; Cao CC; Harpur E
Pharmacol Ther; 2013 Jan; 137(1):100-7. PubMed ID: 23017937
[TBL] [Abstract][Full Text] [Related]
10. An integrated approach to improved toxicity prediction for the safety assessment during preclinical drug development using Hep G2 cells.
Noor F; Niklas J; Müller-Vieira U; Heinzle E
Toxicol Appl Pharmacol; 2009 Jun; 237(2):221-31. PubMed ID: 19332084
[TBL] [Abstract][Full Text] [Related]
11. A translational approach to detecting drug-induced cardiac injury with cardiac troponins: consensus and recommendations from the Cardiac Troponins Biomarker Working Group of the Health and Environmental Sciences Institute.
Berridge BR; Pettit S; Walker DB; Jaffe AS; Schultze AE; Herman E; Reagan WJ; Lipshultz SE; Apple FS; York MJ
Am Heart J; 2009 Jul; 158(1):21-9. PubMed ID: 19540388
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers and mechanisms of drug-induced vascular injury in non-rodents.
Louden C; Brott D; Katein A; Kelly T; Gould S; Jones H; Betton G; Valetin JP; Richardson RJ
Toxicol Pathol; 2006; 34(1):19-26. PubMed ID: 16507540
[TBL] [Abstract][Full Text] [Related]
13. The scope and requirements related to preclinical and clinical studies of a new medicinal product, including biotechnological and biosimilar products.
Brodniewicz-Proba T
Acta Pol Pharm; 2008; 65(6):641-5. PubMed ID: 19172845
[TBL] [Abstract][Full Text] [Related]
14. The application of ICH S6 to the preclinical safety evaluation of plasma derivative therapeutic products.
Lewis RM; Cavagnaro J
Biologicals; 2010 Jul; 38(4):494-500. PubMed ID: 20359910
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics for drug toxicity.
Gao Y; Holland RD; Yu LR
Brief Funct Genomic Proteomic; 2009 Mar; 8(2):158-66. PubMed ID: 19351682
[TBL] [Abstract][Full Text] [Related]
16. A strategic view on the use of pharmacodynamic biomarkers in early clinical drug development.
Severino ME; Dubose RF; Patterson SD
IDrugs; 2006 Dec; 9(12):849-53. PubMed ID: 17139572
[TBL] [Abstract][Full Text] [Related]
17. Novel biomarkers of acute kidney toxicity.
Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
[TBL] [Abstract][Full Text] [Related]
18. Application of genomics in preclinical drug safety evaluation.
Lord PG; Nie A; McMillian M
Basic Clin Pharmacol Toxicol; 2006 Jun; 98(6):537-46. PubMed ID: 16700814
[TBL] [Abstract][Full Text] [Related]
19. Biomedical imaging in the safety evaluation of new drugs.
Wang YX; Yan SX
Lab Anim; 2008 Oct; 42(4):433-41. PubMed ID: 18782821
[TBL] [Abstract][Full Text] [Related]
20. Monitoring of human populations for early markers of cadmium toxicity: a review.
Fowler BA
Toxicol Appl Pharmacol; 2009 Aug; 238(3):294-300. PubMed ID: 19433102
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
